Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 337,919 shares, a growth of 172.8% from the May 31st total of 123,876 shares. Based on an average daily trading volume, of 1,213,060 shares, the days-to-cover ratio is presently 0.3 days. Approximately 27.7% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Aspire Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of ASBP. CIBC Bancorp USA Inc. acquired a new position in shares of Aspire Biopharma during the 3rd quarter valued at about $28,000. XTX Topco Ltd grew its holdings in shares of Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after purchasing an additional 237,620 shares during the period. Finally, Jane Street Group LLC increased its position in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after purchasing an additional 131,533 shares during the last quarter. 19.17% of the stock is owned by institutional investors and hedge funds.

Aspire Biopharma Price Performance

ASBP stock opened at $6.00 on Monday. The business has a 50 day simple moving average of $5.97 and a 200-day simple moving average of $44.14. The firm has a market capitalization of $7.80 million, a PE ratio of -0.05 and a beta of 0.17. Aspire Biopharma has a 1 year low of $3.31 and a 1 year high of $1,050.36.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($20.57) EPS for the quarter. The company had revenue of $0.03 million during the quarter.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.